Today, nearly all Americans agree that drug prices are too high. The average annual per capita spending on medications is over $1,000 and climbing. These sky-high costs burden working-class families with yet another expense, reducing their ability to save, invest, or buy other needed items.
In response to this urgent matter, politicians are singling out pharmacy benefit managers (PBMs), the financial negotiators between pharmaceutical companies and pharmacies. The Federal Trade Commission (FTC) released a report in 2024 accusing PBMs of price-gouging and is currently suing one of these managers over insulin prices. The House Oversight Committee has made PBMs the primary target of its drug price-fighting efforts, rehashing the FTC’s accusations of profiteering.





